SALIX PHARMACEUTICALS WILL PRESENT SCIENTIFIC DATA AT THE SOCIETY OF HOSPITAL MEDICINE CONVERGE 2022
Salix Pharmaceuticals, part of Bausch Health Companies (BHC), announced it will present four research posters at the Society of Hospital Medicine (SHM) Converge 2022, held from April 7-10 in Nashville, TN. The featured studies cover XIFAXAN® (rifaximin) for hepatic encephalopathy and RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation. Key findings include XIFAXAN’s effectiveness in reducing emergency department visits and RELISTOR’s safety profiles. These presentations aim to enhance awareness of treatment options in gastroenterology.
- Presentation of four research posters at a major medical conference enhances visibility and credibility in the gastroenterology sector.
- XIFAXAN is shown to reduce emergency department visits for hepatic encephalopathy, indicating strong clinical utility.
- Potential risks associated with XIFAXAN include increased systemic exposure in patients with severe hepatic impairment.
- RELISTOR's contraindications due to gastrointestinal obstruction highlight some safety concerns.
Featured Posters Will Include XIFAXAN® (rifaximin) and RELISTOR® (methylnaltrexone bromide) Research
BRIDGEWATER, N.J., April 7, 2022 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), the gastroenterology business of Bausch Health Companies Inc. (NYSE/TSX: BHC) and one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, announced today that four posters featuring data for XIFAXAN® (rifaximin) and RELISTOR® (methylnaltrexone bromide) will be presented at the Society of Hospital Medicine (SHM) Converge 2022 annual meeting taking place in Nashville, Tenn. on April 7-10, 2022.
The complete list of Salix research being featured at SHM Converge 2022 includes:
XIFAXAN
- Volk, Michael et al. "Rifaximin Treatment for Hepatic Encephalopathy Reduces Number of Days with Emergency Department Services Versus Lactulose Alone: A Claims Database Analysis"
RELISTOR
- Sayuk, Gregory et al. "Attenuation of Adverse Events Over 7 Doses in Methylnaltrexone-Treated Patients With Opioid-Induced Constipation and Severe Medical Illness"
- Peacock, Frank et al. "Approved Opioid-Induced Constipation Medication Use in Emergency Department Patients With Opioid-Induced Constipation"
- Sayuk, Gregory et al. "Efficacy of Methylnaltrexone in Patients With Advanced Illness and Opioid-Induced Constipation Refractory to Conventional Laxatives: Impact of Baseline Laxative Use"
About XIFAXAN®
Indications
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
IMPORTANT SAFETY INFORMATION
- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
- Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
- There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
- Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
- In clinical studies, the most common adverse reactions for XIFAXAN were:
- HE (≥
10% ): Peripheral edema (15% ), nausea (14% ), dizziness (13% ), fatigue (12% ), and ascites (11% ) - IBS-D (≥
2% ): Nausea (3% ), ALT increased (2% ) - INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
- XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.
To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please click here for full Prescribing Information.
About RELISTOR
RELISTOR® (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
RELISTOR injection is also indicated for the treatment of OIC in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care.
IMPORTANT SAFETY INFORMATION
- RELISTOR tablets and injection are contraindicated in patients with known or suspected mechanical gastrointestinal obstruction and patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.
- Cases of gastrointestinal perforation have been reported in adult patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the gastrointestinal tract (e.g., peptic ulcer disease, Ogilvie's syndrome, diverticular disease, infiltrative gastrointestinal tract malignancies or peritoneal metastases). Take into account the overall risk-benefit profile when using RELISTOR in patients with these conditions or other conditions which might result in impaired integrity of the gastrointestinal tract wall (e.g., Crohn's disease). Monitor for the development of severe, persistent, or worsening abdominal pain; discontinue RELISTOR in patients who develop this symptom.
- If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their health care provider.
- Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, and yawning have occurred in patients treated with RELISTOR. Patients having disruptions to the blood-brain barrier may be at increased risk for opioid withdrawal and/or reduced analgesia and should be monitored for adequacy of analgesia and symptoms of opioid withdrawal.
- Avoid concomitant use of RELISTOR with other opioid antagonists because of the potential for additive effects of opioid receptor antagonism and increased risk of opioid withdrawal.
- The use of RELISTOR during pregnancy may precipitate opioid withdrawal in a fetus due to the immature fetal blood-brain barrier and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because of the potential for serious adverse reactions, including opioid withdrawal, in breastfed infants, advise women that breastfeeding is not recommended during treatment with RELISTOR. In nursing mothers, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
- A dosage reduction of RELISTOR tablets and RELISTOR injection is recommended in patients with moderate and severe renal impairment (creatinine clearance less than 60 mL/minute as estimated by Cockcroft-Gault). No dosage adjustment of RELISTOR tablets or RELISTOR injection is needed in patients with mild renal impairment.
- A dosage reduction of RELISTOR tablets is recommended in patients with moderate (Child-Pugh Class B) or severe (Child- Pugh Class C) hepatic impairment. No dosage adjustment of RELISTOR tablets is needed in patients with mild hepatic impairment (Child-Pugh Class A). No dosage adjustment of RELISTOR injection is needed for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, monitor for methylnaltrexone-related adverse reactions and dose adjust per Prescribing Information as may be indicated.
- In the clinical studies, the most common adverse reactions were:
OIC in adult patients with chronic non-cancer pain - RELISTOR tablets (≥
2% of RELISTOR patients and at a greater incidence than placebo): abdominal pain (14% ), diarrhea (5% ), headache (4% ), abdominal distention (4% ), vomiting (3% ), hyperhidrosis (3% ), anxiety (2% ), muscle spasms (2% ), rhinorrhea (2% ), and chills (2% ). - RELISTOR injection (≥
1% of RELISTOR patients and at a greater incidence than placebo): abdominal pain (21% ), nausea (9% ), diarrhea (6% ), hyperhidrosis (6% ), hot flush (3% ), tremor (1% ), and chills (1% ). - OIC in adult patients with advanced illness
- RELISTOR injection (≥
5% of RELISTOR patients and at a greater incidence than placebo): abdominal pain (29% ) flatulence (13% ), nausea (12% ), dizziness (7% ), and diarrhea (6% ).
To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800- FDA-1088 or www.fda.gov/medwatch.
Please click here for full Prescribing Information for RELISTOR tablets and RELISTOR injection.
About Salix
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Bausch Health Companies Inc. (Bausch Health) most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration, and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
©2022 Salix Pharmaceuticals or its affiliates.
The XIFAXAN 550 mg product and the XIFAXAN trademark are licensed by Alfasigma S.p.A. to Salix Pharmaceuticals or its affiliates.
RELISTOR is a trademark of Salix Pharmaceuticals or its affiliates.
SAL.0055.USA.22
View original content to download multimedia:https://www.prnewswire.com/news-releases/salix-pharmaceuticals-will-present-scientific-data-at-the-society-of-hospital-medicine-converge-2022-301519621.html
SOURCE Salix Pharmaceuticals, Ltd.
FAQ
What will Salix Pharmaceuticals present at SHM Converge 2022 regarding BHC?
When is the SHM Converge 2022 conference?
What studies will be featured related to XIFAXAN?
What safety information was highlighted for RELISTOR?
What is the significance of the findings at the SHM Converge 2022 for BHC investors?
